Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Dermatologic ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Epidemiology of Melanoma.Med Sci (Basel). 2021; 9: 63
- Melanoma: Cutaneous (version 1.2022).(Available at:) (Accessed December 5, 2021)
- Melanoma of the Skin-Cancer Stat Facts.(Available online:) (Accessed on December 3, 2021)
- Improved survival with vemurafenib in melanoma with BRAF V600E mutation.N Engl J Med. 2011; 364: 2507-2516
- Cancer Statistics.CA Cancer J Clin. 2020; 70: 7-30
- Current Advances in the Treatment of BRAF-Mutant Melanoma.Cancers. 2020; 12: 482
- Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma.Pigment Cell Melanoma Res. 2020; 33: 390-402
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM- 3): Extended follow-up of a phase 3, randomised, open-label study.Lancet Oncol. 2014; 15: 323-332
- Vemurafenib in patients with BRAFV600 mutation- positive metastatic melanoma: Final overall sur- vival results of the randomized BRIM-3 study.Ann Oncol. 2017; 28: 2581-2587
- Comprehensive clinical trial data summation for BRAF-MEK inhibition and checkpoint immunotherapy in metastatic melanoma.Oncologist. 2019; 24: e1197-e1211
- Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial.Lancet. 2012; 380: 358-365
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): A multicentre, open-label, randomised, phase 3 trial.Lancet Oncol. 2018; 19: 1315-1327
- Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.J Am Acad Dermatol. 2015; 72: 809-815
- Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy.OncoTargets Ther. 2018; 11: 9081
- Resistant mechanisms to BRAF inhibitors in melanoma.Ann Transl Med. 2016; 4: 237
- Trametinib: a targeted therapy in metastatic melanoma.J Adv Pract Oncol. 2018; 9: 741-745
- Improved survival with MEK inhibition in BRAF-mutated melanoma.N Engl J Med. 2012; 367: 107-114
- Overall survival (OS) update on METRIC (NCT01245062), a randomized phase 3 study to assess efficacy of trametinib (T) compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutation-positive (+) advanced or metastatic melanoma (MM).Pigment Cell Melanoma Res. 2013; 26: 997A
- Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.Eur J Cancer. 2019; 109: 61-69
- Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicenter, open-label, randomsied, phase 3 trial.Lancet Oncol. 2017; 18: 435-445
- Combined vemurafenib and cobimetenib in BRAF-mutated melanoma.N Engl J Med. 2014; 371: 1867-1876
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM):Updated efficacy results from a randomised, double-blind, phase 3 trial.Lancet Oncol. 2016; 17: 1248-1260
- Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive metastatic melanoma: Analysis from the 4-year extended follow-up of the phase 3 coBRIM study.J Clin Oncol. 2018; 36: 9522A
- Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.N Engl J Med. 2014; 71: 1877-1888
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial.Lancet. 2015; 386: 444-451
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/k-mutant melanoma: Long-term survival and safety analysis of a phase 3 study.Ann Oncol. 2017; 28: 1631-1639
- Improved overall survival in melanoma with combined dabrafenib and trametinib.N Engl J Med. 2015; 372: 30-39
- Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/k-mutant cutaneous melanoma.Ann Oncol. 2016; 27: LBA40A
- Results of COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in BRAF-mutant melanoma.Oral presentation Annu Soc Melanoma Res Meet. 2016;
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial.Lancet Oncol. 2018; 19: 603-615
- Results of COLUMBUS part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma.Ann Oncol. 2017; 28: 1215OA
- Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.J Am Acad Dermatol. 2014; 71: 1102-1109
- Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: A meta-analysis.Oncotarget. 2017; 8: 83280-83291
- Immune system and melanoma biology: a balance between immunosurveillance and immune escape.Oncotarget. 2017; 8: 106132-106142
- Principles of immunotherapy in melanoma.Surg Clin North Am. 2020; 100: 161-173
- Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med. 2010; 363: 711-723
- Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.N Engl J Med. 2011; 364: 2517-2526
- Nivolumab in previously untreated melanoma without BRAF mutation.N Engl J Med. 2015; 372: 320-330
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial.Lancet Oncol. 2015; 16: 375-384
- Overall survival in patients with advanced melanoma who received nivolumab vs investigator's choice chemotherapy in the phase 3 CheckMate 037 trial.Oral presentation Annu Soc Melanoma Res Meet. 2016;
- Pembrolizumab versus ipilimumab in advanced melanoma.N Engl J Med. 2015; 372: 2521-2532
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).Lancet. 2017; 390: 1853-1862
- 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.J Clin Oncol. 2018; 36: 9503A
- ESMO Consensus Conference Recommendations on the Management of Metastatic Melanoma: Under the Auspices of the ESMO Guidelines Committee.Ann Oncol. 2020; 31: 1435-1448
- Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma.J Clin Oncol. 2018; 36: 1668-1674
- Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: Clinical outcomes in advanced melanoma.Ann Oncol. 2019; 30: 1154-1161
- Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.N Engl J Med. 2015; 372: 2006-2017
- Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.N Engl J Med. 2015; 373: 23-34
- Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).J Clin Oncol. 2016; 34: 9505A
- Overall survival with combined nivolumab and ipilimumab in advanced melanoma.N Engl J Med. 2017; 377: 1345-1356
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multi- centre, randomised, phase 3 trial.Lancet Oncol. 2018; 19: 1480-1492
- Five-year survival with combined nivolumab and ipilimumab in advanced melanoma.N Engl J Med. 2019; 381: 1535-1546
- Management of Immunotherapy-Related Toxicities (version 4.2021).(Available at:) (Accessed December 5, 2021)
- Cutaneous adverse reactions to anti-PD-1 treatment-a systematic review.J Am Acad Dermatol. 2020; 83: 1415-1424
- Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.Ann Oncol. 2021; 32: 917-925
- Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.J Immunother Cancer. 2017; 5: 95
- Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors—A systematic review and meta-analysis.Cancer Treat Rev. 2020; 92: 102134
- Advanced stage melanoma therapies: detailing the present and exploring the future.Crit Rev Oncol Hematol. 2019; 133: 99-111
- Talimogene laherparepvec improves durable response rate in patients with advanced melanoma.J Clin Oncol. 2015; 33: 2780-2788
- Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial.Ann Surg Oncol. 2016; 23: 4169-4177
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.J Clin Oncol. 2017; 36: 9509
- 1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL).Ann Oncol. 2021; 32: S868-S869
- Treatment of in transit melanoma with intra-lesional interleukin-2: A systematic review.Can J Plast Surg. 2013; 21: 142
- Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma.J Surg Oncol. 2014; 109: 308-313
- A quantitative systemic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance.J Am Acad Dermatol. 2015; 73: 205-212
- The role of topical imiquimod in melanoma cutaneous metastases: a critical review of the literature.Dermatol Ther. 2020; 1: e14165
- Keynote-022 Part 3: A Randomized, Double-Blind, Phase 2 Study of Pembrolizumab, Dabrafenib, and Trametinib in BRAF-mutant Melanoma.J Immunother Cancer. 2020; 8: e001806
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.Nat Med. 2019; 25: 941-946
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): Primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2020; 395: 1835-1844
- Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy.N Engl J Med. 2016; 375: 1845-1855
- Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma.N Engl J Med. 2017; 377: 1824-1835
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma.N Engl J Med. 2018; 378: 1789-1801
- Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma.N Engl J Med. 2017; 377: 1813-1823
- Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.Lancet Oncol. 2018; 19: 510-520
- Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.Lancet Oncol. 2018; 19: 181-193
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.Nat Med. 2018; 24: 1649-1654
- Twenty-Four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma.J Clin Oncol. 2020; 38: 10015
- Gut microbiome modulates response to anti -PD-1 immunotherapy in melanoma patients.Science. 2018; 359: 97-103
- Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial.J Clin Oncol. 2018; 36: 383-390
- Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: a randomised clinical trial.Eur J Cancer. 2018; 101: 236-243
- Abstract CT137: Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma.Cancer Res. 2015; 75: CT137
- Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody.Clin Cancer Res. 2017; 23: 1929-1936
- Discovery of IDO1 Inhibitors: From Bench to Bedside.Cancer Res. 2017; 77: 6795-6811
- Interim analysis of the phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma. [AACR abstract CT117].Cancer Res. 2017; 77: CT117
Article info
Publication history
Published online: October 27, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
